Phase II Study of Dostarlimab in Locally Advanced, Mismatch Repair–Deficient Rectal Cancer

Early data showed that among 14 patients with locally advanced, dMMR rectal cancer who completed treatment with the PD-1 inhibitor dostarlimab, all 14 achieved a clinical complete response, without the need for chemoradiotherapy or surgery.